Want to see AU:HLS full AI Analyst Report?
Healius Limited (HLS) Share Price & Analysis
HLS Stock Chart & Stats
- Day’s Range
- AUD 0.48 - AUD 0.51
- 52-Week Range
- AUD 0.30 - AUD 1.07
- Previous Close
- AUD 0.49
- Volume
- 1.06M
- Average Volume (3M)
- 4.70M
- Market Cap
- AUD 359.46M
- Enterprise Value
- AUD 1.21B
- Total Cash (Recent Filing)
- AUD 67.20M
- Total Debt (Recent Filing)
- AUD 998.70M
- Price to Earnings (P/E)
- ―
- Beta
- 1.14
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- -0.01
- Last Dividend Ex-Date
- May 09, 2025
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Persistent Cash Generation
Persistent positive operating and free cash flow show that Healius continues converting diagnostic activity into liquidity despite accounting losses. This supports debt reduction, ongoing operations, and selective investment, providing a durable financial buffer over the next several quarters.
Deleveraging Progress
Meaningful debt reduction improves financial resilience and lowers the burden on future cash flows. Although equity has contracted, continued deleveraging gives Healius greater capacity to manage its obligations and fund the business through changing healthcare demand.
Revenue Recovery
The recovery in revenue indicates renewed demand for Healius's pathology and imaging services after the FY2023 contraction. Sustained top-line improvement would strengthen operating leverage, support network utilisation, and create a better foundation for restoring profitability.
Bears Say
Persistent Net Losses
Four consecutive years of net losses indicate that revenue recovery has not yet translated into durable shareholder earnings. Continued losses can restrict reinvestment, weaken equity, and leave the company more dependent on operating cash flow to support obligations and strategic initiatives.
Weak Margin Quality
Weak and unstable margins suggest Healius has limited earnings conversion from its diagnostic revenue base. Thin operating profitability reduces the cushion against cost pressures or reimbursement changes and makes future earnings improvement dependent on sustained efficiency gains.
Contracted Equity Base
A substantially smaller equity base reduces balance-sheet flexibility and leaves less capacity to absorb further losses. Combined with deeply negative recent returns, this weakens the platform for long-term capital allocation and increases the importance of maintaining positive cash generation.
HLS FAQ
What was Healius Limited’s price range in the past 12 months?
What is Healius Limited’s market cap?
When is Healius Limited’s upcoming earnings report date?
How were Healius Limited’s earnings last quarter?
Is Healius Limited overvalued?
Does Healius Limited pay dividends?
What is Healius Limited’s EPS estimate?
How many shares outstanding does Healius Limited have?
What happened to Healius Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Healius Limited?
What is the TipRanks Smart Score and how is it calculated?
Healius Limited Stock Smart Score
Company Description
Healius Limited
Healius Limited is an Australian firm dedicated to delivering specialized diagnostic services to both individual consumers and healthcare practitioners. Its operations are structured into four primary segments: Pathology, Medical Imaging, Day Hospitals, and other miscellaneous services. The company's core offerings include comprehensive diagnostic imaging, private medical laboratory analysis, and various pathology services. Furthermore, under a diverse portfolio of brands such as Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs, alongside Lumus Imaging and Montserrat, Healius also facilitates a wide array of specialized surgical procedures. These encompass cataract removal, colonoscopies, gastroscopies, plastic and cosmetic operations, skin cancer excisions, IVF egg collection, and gynecological surgeries. The company boasts an extensive network across Australia, comprising 2,105 pathology facilities, 11 day hospitals, and 134 imaging centers. Established in 1994, the entity was originally known as Primary Health Care Limited, adopting the Healius Limited name in December 2018. Its corporate headquarters are situated in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Paul D. Anderson
- Employees
- 6,000
- Website
- www.healius.com.au
- Address
- 161 Castlereagh Street, Sydney, NSW, 2000, AU
Healius Limited (HLS) Earnings & Revenues
HLS Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 2 | 7 |
| Technical Analysis | 2 | 2 | 6 |
| Moving Averages | 11 | 0 | 1 |








